Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allergic Asthma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    354 result(s) found for: Allergic Asthma. Displaying page 2 of 18.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001103-36 Sponsor Protocol Number: 2013RC01 Start Date*: 2013-05-27
    Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside
    Full Title: Randomised controlled single and chronic dosing crossover comparison of extra fine particle formoterol and coarse particle salmeterol in asthmatic patients with persistent small airways dysfunction
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007244-33 Sponsor Protocol Number: LPA112046 Start Date*: 2009-04-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: The efficacy of orally administered GSK2190915 as an add-on to current therapy in subjects with moderate to severe asthma who have elevated sputum neutrophils
    Medical condition: Moderate to severe asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018621-19 Sponsor Protocol Number: MT-04 Start Date*: 2011-09-30
    Sponsor Name:ALK-Abelló A/S
    Full Title: Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial.
    Medical condition: House dust mite induced allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) SK (Completed) LT (Completed) ES (Completed) GB (Completed) AT (Completed) NL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-005094-54 Sponsor Protocol Number: TPI ASM8-205 Start Date*: 2008-01-17
    Sponsor Name:Topigen Pharmaceuticals Inc.
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 14-DAY INHALED TPI ASM8 IN SUBJECTS WITH ASTHMA
    Medical condition: allergic asthma and allergen-induced asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    9.1 10003638 Atopic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000057-23 Sponsor Protocol Number: AV-G-01 Start Date*: 2011-05-26
    Sponsor Name:ALK-Abello S.A.
    Full Title: Estudio abierto para valorar la tolerabilidad de la inmunoterapia con AVANZ Phleum pratense
    Medical condition: Rinoconjuntivitis alérgica con o sin asma debido a la sensibilidad al polen de gramineas.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-002289-33 Sponsor Protocol Number: 601-0018 Start Date*: 2023-02-01
    Sponsor Name:Pulmatrix, Inc.
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on S...
    Medical condition: Allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.1 100000004862 10001707 Allergic bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000674-58 Sponsor Protocol Number: AL1011av Start Date*: 2011-07-28
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: Double-blind, placebo controlled study to investigate the dose response of an allergoid preparation of Phleum pratense in adult patients with IgE mediated allergic Rhinitis / Rhinoconjunctivitis wi...
    Medical condition: ICD classification code: J 45.0 and J 30.1
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039087 Rhinitis allergic NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004775-23 Sponsor Protocol Number: MK-0476-383 Start Date*: 2015-04-08
    Sponsor Name:Merck Frosst Canada Ltd.
    Full Title: RADAR: SingulaiR® in Asthma anD Allergic Rhinitis An 8 week multicenter, open-label, observational study to evaluate the effectiveness of adding Montelukast Sodium (SINGULAIR®) 10 mg per day to inh...
    Medical condition: Adult asthma and allergic rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000126-30 Sponsor Protocol Number: ASM8-A-208 Start Date*: 2011-06-07
    Sponsor Name:Pharmaxis Ltd
    Full Title: A phase II, multi-centre, single blind study to evaluate the safety, tolerability and explore the efficacy of 8.0 mg ASM8 inhaled daily for 14 days in adult subjects with moderate to severe asthma
    Medical condition: moderate to severe asthma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003638 Atopic asthma LLT
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000487-28 Sponsor Protocol Number: VO72.12 Start Date*: 2013-08-20
    Sponsor Name:STALLERGENES SA
    Full Title: A dose ranging study investigating the efficacy and safety of sublingual immunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma
    Medical condition: house dust mite-associated allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10020419 House dust mite allergy LLT
    14.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Ongoing) PL (Completed) BG (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003385-34 Sponsor Protocol Number: CRU.LUMC.001 Start Date*: 2006-11-23
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: The effect of tiotropium-bromide on deep inspiration-induced bronchodilation and airway responsiveness in asthma.
    Medical condition: 24 patients with mild persistent asthma will participate in the study. All patients will be allergic to one or more airborne allergens, hyperresponsive to histamine (PC20 < 8 mg/ml) and have a norm...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003638 Atopic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004363-39 Sponsor Protocol Number: MT-11 Start Date*: 2018-03-15
    Sponsor Name:ALK-Abelló A/S
    Full Title: A phase III trial evaluating the efficacy and safety of the house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet in children and adolescents (5-17 years) with HDM allergic asthma
    Medical condition: House Dust Mite (HDM) Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Temporarily Halted) HU (Completed) BG (Completed) DK (Completed) FR (Completed) PL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-000586-12 Sponsor Protocol Number: MATERIAL Start Date*: 2011-11-08
    Sponsor Name:Academic Medical Center
    Full Title: The efficacy of mepolizumab treatment on rhinovirus induced asthma exacerbations
    Medical condition: Asthma and more specifically virus-induced exacerbations in allergic asthma patients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015575 Exacerbation of asthma LLT
    12.1 10001705 Allergic asthma LLT
    12.1 10049868 Asthma exacerbation prophylaxis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001209-41 Sponsor Protocol Number: AC-060A201 Start Date*: 2008-07-25
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multi-center, double-blind, placebo-controlled, randomized, multiple dose, 2-period cross-over, Phase IIa study to investigate the pharmacodynamics, tolerability and safety, and pharmacokinetics ...
    Medical condition: Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001062-18 Sponsor Protocol Number: CQAW039A2206 Start Date*: 2011-09-02
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1-450 mg p.o.), to investigate the effect on FEV1 and ACQ in patients with moderate-to-severe, persistent, allergic ast...
    Medical condition: Moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed) GB (Completed) AT (Completed) HU (Completed) PL (Completed) NL (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-004748-37 Sponsor Protocol Number: MK-0476-367 Start Date*: 2015-04-03
    Sponsor Name:MSD Korea LTD.
    Full Title: Korean Study of “Real-world” Montelukast Use in Mild Asthmatic Children with Concomitant Allergic Rhinitis
    Medical condition: mild asthma and allergic rhinitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000737-12 Sponsor Protocol Number: LPI-1201 Start Date*: 2013-09-09
    Sponsor Name:Lallemand Pharma International AG
    Full Title: The Influence of Polyvalent Mechanical Bacterial Lysate (ISMIGEN®) on Clinical Course of Asthma and Related Immunological parameters in Asthmatic Children (EOLIA Study): Randomized, Double Blind, P...
    Medical condition: IgE-dependent asthma (diagnosis of asthma according to the GINA definition) in a paediatric population (6 thru 16 years old)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000047-99 Sponsor Protocol Number: MK-0476P2181V1 Start Date*: 2007-03-06
    Sponsor Name:Tari Haahtela
    Full Title: Montelukast as a controller of atopic syndrome - MONTAS-study
    Medical condition: Allergic symptoms (rhinitis, conjunctivits, asthma, oral symptoms and atopic eczema) caused by pollen allergy to birch or timothy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    20.0 100000004858 10003641 Atopic eczema LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-010914-31 Sponsor Protocol Number: CHD-PI08 Start Date*: 2009-12-02
    Sponsor Name:Dr. Christian Domingo
    Full Title: Eficacia clínica y cambios histológicos secundarios al tratamiento con omalizumab en asmáticos alérgicos en estadio V de la gina
    Medical condition: Asma
    Disease: Version SOC Term Classification Code Term Level
    9 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003860-47 Sponsor Protocol Number: CIGE025ADE03 Start Date*: 2006-02-20
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, 20 week, double-blind, placebo-controlled, parallel-group, multiple-dose, multicenter study to assess the efficacy and safety of Omalizumab in combination with Depigoid, versus Depigo...
    Medical condition: Asthma extrinsic
    Disease: Version SOC Term Classification Code Term Level
    M15 10003558 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 03 03:07:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA